List of bibliographic references
Number of relevant bibliographic references: 4.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Adult |
| 3 | Female |
| 3 | Humans |
| 3 | Male |
| 3 | Middle Aged |
| 2 | Adolescent |
| 2 | Aged |
| 2 | Antiviral Agents (therapeutic use) |
| 2 | Drug Therapy, Combination |
| 2 | Hepatitis B Surface Antigens (blood) |
| 2 | Hepatitis B, Chronic (blood) |
| 2 | Hepatitis B, Chronic (drug therapy) |
| 2 | Tenofovir (therapeutic use) |
| 2 | Treatment Outcome |
| 2 | Young Adult |
| 1 | Administration, Oral |
| 1 | Aged, 80 and over |
| 1 | Antiviral Agents (administration & dosage) |
| 1 | Antiviral Agents (adverse effects) |
| 1 | Biomarkers (blood) |
| 1 | Carbamates (administration & dosage) |
| 1 | Carbamates (adverse effects) |
| 1 | Carbamates (therapeutic use) |
| 1 | DNA, Viral (analysis) |
| 1 | Dose-Response Relationship, Drug |
| 1 | Double-Blind Method |
| 1 | Drug Administration Schedule |
| 1 | Follow-Up Studies |
| 1 | Hepatitis B Surface Antigens (drug effects) |
| 1 | Hepatitis B e Antigens (blood) |
| 1 | Hepatitis B virus (genetics) |
| 1 | Hepatitis B virus (immunology) |
| 1 | Hepatitis B, Chronic (diagnosis) |
| 1 | Hepatitis B, Chronic (mortality) |
| 1 | Hepatitis B, Chronic (virology) |
| 1 | Hepatitis C, Chronic (drug therapy) |
| 1 | Heterocyclic Compounds, 4 or More Rings (administration & dosage) |
| 1 | Heterocyclic Compounds, 4 or More Rings (adverse effects) |
| 1 | Heterocyclic Compounds, 4 or More Rings (therapeutic use) |
| 1 | High-Throughput Nucleotide Sequencing |
| 1 | Injections, Subcutaneous |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Internationality |
| 1 | Kaplan-Meier Estimate |
| 1 | Macrocyclic Compounds (administration & dosage) |
| 1 | Macrocyclic Compounds (adverse effects) |
| 1 | Macrocyclic Compounds (therapeutic use) |
| 1 | Markov Chains |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | Prognosis |
| 1 | Promoter Regions, Genetic |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Risk Assessment |
| 1 | Sequence Analysis, DNA |
| 1 | Seroconversion |
| 1 | Severity of Illness Index |
| 1 | Sofosbuvir (administration & dosage) |
| 1 | Sofosbuvir (adverse effects) |
| 1 | Sofosbuvir (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (adverse effects) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Survival Rate |
| 1 | Sustained Virologic Response |
| 1 | Viral Load |
| 1 | Viral Load (drug effects) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "G Mani Subramanian"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "G Mani Subramanian" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= G Mani Subramanian
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
